Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.
Direct-to-consumer telehealth platform selling subscription-based treatments for men's/women's health, mental health, weight loss and dermatology.
Customers pay monthly or by plan for medication shipped from its own pharmacies, with the consultation by affiliated clinicians included, so revenue is mostly recurring and depends on subscriber retention and what each subscriber buys. Online advertising drives customer acquisition. Some products are compounded versions of branded drugs, a regulatory-sensitive area.
Moat: narrow (brand, scale, data). Strong direct-to-consumer brand and marketing scale in a category with growing but not-yet-entrenched telehealth competitors.
Headquarters: San Francisco, California, USA · Founded: 2017 · Employees: 2,442
Size Hims & Hers Health (HIMS) is a United States Health Care company (Medical/Nursing Services) with a market value of $4.00B, the 1341st largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.05 on 18 Nov 2026.
Performance Over six months the shares fell 26.0%, against +28.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 29.8% over the last twelve months (peer median +11.3%); the operating margin is -1.4% (peer median 8.9%).
Valuation It trades at 1.7× enterprise value to sales against a peer median of 2.3× (7th cheapest of 21).
Capital Return on invested capital runs 16.9 points below its cost of capital (14.3% WACC).
Credit Hims & Hers Health has 1 bond outstanding ($1.00B).
Short interest Short interest is 23.0% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.87B | $2.35B | $1.48B | $872M | $527M |
| Revenue growth | — | +59% | +69% | +65% | — |
| Gross profit | $1.43B | $1.39B | $970M | $705M | $401M |
| EBITDA | $67.5M | $176M | $85.1M | -$23.9M | -$61.0M |
| Net income | -$191M | $128M | $126M | -$23.5M | -$65.7M |
| Free cash flow | $11.6M | $57.4M | $198M | $47.0M | -$33.8M |
| Capital expenditure | $172M | $243M | $52.8M | $26.5M | $7.25M |
| Total debt | $1.56B | $1.12B | $11.3M | $9.95M | $5.31M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hims & Hers Health HIMS | $4.00B | -26% | +30% | -1% | 1.7× | n/a |
| Teladoc Health TDOC | $1.47B | +24% | -2% | -5% | 0.7× | -6.4% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| GoodRx GDRX | $1.15B | +33% | -2% | 12% | 1.8× | 6.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HIMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -41.6% | +2.8% | lowest of 21 |
| 6-month return | -26.0% | +28.9% | 3rd lowest of 20 |
| Distance from 52-week high | -58.4% | -10.5% | lowest of 21 |
| Revenue growth (TTM) | +29.8% | +11.3% | 3rd highest of 21 |
| Operating margin | -1.4% | 8.9% | 3rd lowest of 21 |
| EV / Sales | 1.7× | 2.3× | 7th cheapest of 21 |
| ROIC minus cost of capital | -16.9 pp | +0.0 pp | lowest of 21 |
| Net debt / EBITDA | 12.6× | 2.6× | 2nd most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hims & Hers Health HIMS | United States | $4.00B | -26% | +30% | -1% | 1.7× | n/a | n/a |
| Medicover MCOV-B.ST | Sweden | $3.87B | +21% | +3% | 7% | 2.0× | 19.6% | +20.2% |
| BillionToOne BLLN | United States | $4.37B | +7% | +72% | 10% | 9.1× | 22.8% | +71.9% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.53B | +15% | +17% | 24% | 10.4× | 32.3% | +11.8% |
| Fameglow 3774.HK | Hong Kong | $4.54B | n/a | +36% | 11% | 60.4× | 57.4% | +48.4% |
| Acadia Healthcare ACHC | United States | $3.49B | +56% | +4% | 10% | 1.8× | n/a | n/a |
| Option Care Health OPCH | United States | $4.75B | +43% | +4% | 6% | 1.0× | 2.0% | +13.2% |
| Lifestance Health LFST | United States | $5.24B | +79% | +23% | 6% | 3.3× | 33.4% | +30.4% |
| Concentra Group Holdings Parent CON | United States | $5.31B | +65% | +12% | 17% | 3.2× | 3.6% | +7.9% |
| RadNet RDNT | United States | $5.66B | +32% | +21% | 5% | 3.1× | 38.8% | +13.7% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 2.2× | 4.2% | +5.7% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 1.3× | -4.4% | +2.0% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 1.4× | 7.7% | +10.2% |
| Sonic Healthcare SHL.AX | Australia | $6.87B | +6% | +14% | 9% | 1.4× | 9.1% | +3.5% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 1.5× | 4.0% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 2.5× | 21.1% | +14.6% |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 2.8× | 38.0% | +3.9% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 2.9× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 7.8× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 1.9× | 5.4% | -6.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | 1.6× | 21.2% | +8.5% |
Hims & Hers Health has 1 bond outstanding with $1.00B face value.